Paul G Rubinstein
Overview
Explore the profile of Paul G Rubinstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
394
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lurain K, El Zarif T, Ramaswami R, Nassar A, Adib E, Abdel-Wahab N, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
24(12):873.
PMID: 39603773
No abstract available.
2.
Rubinstein P, Galvez C, Ambinder R
Curr Opin Infect Dis
. 2024 May;
37(4):254-263.
PMID: 38820072
Purpose Of Review: Summarize the latest research of both stem cell transplantation and cellular therapy and present the implications with respect to persons with HIV (PWH), hematologic malignancies, and HIV-1...
3.
Lurain K, El Zarif T, Ramaswami R, Nassar A, Adib E, Abdel-Wahab N, et al.
Clin Lymphoma Myeloma Leuk
. 2024 May;
24(8):523-530.
PMID: 38714474
Background: Despite a higher risk of classical Hodgkin lymphoma (cHL) in people with HIV and the demonstrated safety and efficacy of PD-1 blockade in cHL, there are limited data on...
4.
Morales A, Gumenick R, Genovese C, Jang Y, Ouedraogo A, Ibanez de Garayo M, et al.
PLoS Pathog
. 2024 Jan;
20(1):e1011881.
PMID: 38190392
In people living with HIV, Kaposi Sarcoma (KS), a vascular neoplasm caused by KS herpesvirus (KSHV/HHV-8), remains one of the most common malignancies worldwide. Individuals living with HIV, receiving otherwise...
5.
Rajdev L, Jackie Wang C, Joshi H, Lensing S, Lee J, Ramos J, et al.
Cancer
. 2023 Nov;
130(6):985-994.
PMID: 37962072
Background: Although immunotherapy has emerged as a therapeutic strategy for many cancers, there are limited studies establishing the safety and efficacy in people living with HIV (PLWH) and cancer. Methods:...
6.
Rubinstein P, Moore P, Bimali M, Lee J, Rudek M, Chadburn A, et al.
Lancet Haematol
. 2023 Aug;
10(8):e624-e632.
PMID: 37532416
Background: Brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (AVD) is approved in the upfront setting for advanced stage classical Hodgkin lymphoma (cHL). People living with HIV have been...
7.
El Zarif T, Nassar A, Adib E, Fitzgerald B, Huang J, Mouhieddine T, et al.
J Clin Oncol
. 2023 May;
41(21):3712-3723.
PMID: 37192435
Purpose: Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity...
8.
Zayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, et al.
Blood Adv
. 2023 May;
7(21):6381-6394.
PMID: 37171397
In this multi-institutional retrospective study, we examined the characteristics and outcomes of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS)-a rare category defined by high-grade morphologic features and...
9.
Thomas N, Dreval K, Gerhard D, Hilton L, Abramson J, Ambinder R, et al.
Blood
. 2022 Oct;
141(8):904-916.
PMID: 36201743
Burkitt lymphoma (BL) accounts for most pediatric non-Hodgkin lymphomas, being less common but significantly more lethal when diagnosed in adults. Much of the knowledge of the genetics of BL thus...
10.
Mahale P, Nomburg J, Song J, Steinberg M, Starrett G, Boland J, et al.
Infect Agent Cancer
. 2021 Nov;
16(1):65.
PMID: 34775986
Systemic anaplastic large cell lymphoma (ALCL) is a rare CD30-expressing T-cell non-Hodgkin lymphoma. Risk of systemic ALCL is highly increased among immunosuppressed individuals. Because risk of cancers associated with viruses...